EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Cerebrospinal Fluid Biomarkers in Opioid Dependence: Evidence of Neuroimmune Activation and Ion Composition Changes, Without Alteration in Orexin‐A

Tim Lyckenvik, Malin Woock iD, Kalle Johansson iD, Markus Axelsson, Henrik Zetterberg, Kaj Blennow, Eric Hanse, Pontus Wasling iD

Addiction Biology · 2025

DOI: 10.1111/adb.70053 ↗

At a glance

Journal article in Addiction Biology, 2025. Written by Tim Lyckenvik and 7 co-authors. Institution: Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. Major MEDLINE topics: Orexins, Opioid-Related Disorders. 43 references. The full text is freely available (open access, CC BY 4.0). Funded by: Swedish Research Council, European Union's Horizon Europe, Swedish State Support for Clinical Research.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Opioid abuse is a severe global health challenge, leading to rising morbidity, mortality, and increasing societal costs. The aim of this study was to investigate neuroinflammation, neuronal damage and potential changes in the orexin system or beta‐amyloid metabolism in the cerebrospinal fluid (CSF) of individuals undergoing opioid substitution therapy (OST). This cross‐sectional study investigates CSF biomarkers in individuals undergoing OST, compared to control subjects. Participants receiving OST were recruited from the outpatient clinic at the Department of Psychiatry, Sahlgrenska University Hospital, Gothenburg (Sweden). Each participant provided a complete medical history, including details of drug use over the past 6 months, followed by a lumbar puncture to obtain CSF samples. Molecules associated with neuroinflammation, neuronal and glial damage, beta‐amyloid metabolism and orexinergic function were analysed in the participants' CSF, alongside electrolyte levels. Specifically, we analysed levels of sTREM‐2, YKL‐40, IL‐1β, IL‐6, IL‐8, IL‐10, TNF‐α, AXL, MER, TYRO3, GAS6, NfL, GFAP, total tau (T‐tau), phosphorylated tau (P‐tau), neurogranin, Aβ40, Aβ42, the Aβ42/Aβ40 ratio, orexin‐A, sPDGFR‐β and electrolytes. The study included 15 control subjects and 17 in the opioid substitution group. Patients undergoing opioid substitution therapy exhibited elevated levels of sTREM‐2, Aβ42/Aβ40 ratio and NfL in their CSF. Conversely, concentrations of Na + and Cl − were lower compared to controls. No significant differences were found between groups for other biomarkers, including orexin‐A. However, when normalized to Aβ40 levels, YKL‐40, IL‐8, TYRO3 and P‐Tau were also elevated in individuals with opioid dependence. Elevated biomarkers of neuroimmune activation, neuronal damage and beta‐amyloid metabolism in opioid dependence suggest CNS inflammation as a contributor to its pathophysiology. Reduced electrolyte levels imply disrupted CSF water regulation, possibly linked to impaired glial function. These findings highlight both neural and non‐neural mechanisms in opioid dependence.

Subjects

MeSH terms (MEDLINE)

OrexinsOpioid-Related DisordersHumansBiomarkersMaleFemaleCross-Sectional StudiesAdultAmyloid beta-PeptidesMiddle AgedOpiate Substitution TreatmentChitinase-3-Like Protein 1

Substances

OrexinsBiomarkersAmyloid beta-PeptidesChitinase-3-Like Protein 1CHI3L1 protein, human

Authors and institutions

  • Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, United States.

ORCID profiles: Malin Woock, Kalle Johansson, Pontus Wasling

Funding

  • Swedish Research Council
  • European Union's Horizon Europe
  • Swedish State Support for Clinical Research
  • Stiftelsen för Gamla Tjänarinnor
  • Alzheimer's Drug Discovery Foundation
  • the AD Strategic Fund and the Alzheimer's Association
  • NEuroBioStand
  • Hjärnfonden

Cite

APA

Lyckenvik, T., Woock, M., Johansson, K., Axelsson, M., Zetterberg, H., Blennow, K., Hanse, E., & Wasling, P. (2025). Cerebrospinal Fluid Biomarkers in Opioid Dependence: Evidence of Neuroimmune Activation and Ion Composition Changes, Without Alteration in Orexin‐A. Addiction Biology. https://doi.org/10.1111/adb.70053

Vancouver

Lyckenvik T, Woock M, Johansson K, Axelsson M, Zetterberg H, Blennow K, et al. Cerebrospinal Fluid Biomarkers in Opioid Dependence: Evidence of Neuroimmune Activation and Ion Composition Changes, Without Alteration in Orexin‐A. Addiction Biology. 2025. doi:10.1111/adb.70053

BibTeX
@article{Lyckenvik2025,
  author = {Lyckenvik, Tim and Woock, Malin and Johansson, Kalle and Axelsson, Markus and Zetterberg, Henrik and Blennow, Kaj and Hanse, Eric and Wasling, Pontus},
  title = {Cerebrospinal Fluid Biomarkers in Opioid Dependence: Evidence of Neuroimmune Activation and Ion Composition Changes, Without Alteration in Orexin‐A},
  journal = {Addiction Biology},
  year = {2025},
  doi = {10.1111/adb.70053}
}
Start for free →